Equities

Immunitybio Inc

Immunitybio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)5.07
  • Today's Change0.035 / 0.70%
  • Shares traded2.71m
  • 1 Year change+21.00%
  • Beta0.7548
Data delayed at least 15 minutes, as of Nov 22 2024 20:20 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its proprietary platforms that amplify both the innate and adaptive branches of the immune system, its advances therapies and vaccines to defeat urologic and other cancers, as well as infectious diseases. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising, B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA and recombinant protein vaccines, and cell therapies. Its lead biologic commercial product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein.

  • Revenue in USD (TTM)7.33m
  • Net income in USD-587.79m
  • Incorporated2014
  • Employees672.00
  • Location
    Immunitybio Inc3530 JOHN HOPKINS COURTSAN DIEGO 92121United StatesUSA
  • Phone+1 (858) 633-0300
  • Fax+1 (302) 674-5266
  • Websitehttps://immunitybio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vera Therapeutics Inc0.00-134.38m2.98bn82.00--8.95-----2.60-2.600.005.250.00----0.00-49.39---54.50--------------0.1487-------7.79------
Xenon Pharmaceuticals Inc0.00-213.39m3.02bn251.00--3.78-----2.81-2.810.0010.530.00----0.00-28.32-20.71-29.38-21.81-------683.58----0.00---100.00---45.99--61.77--
Veracyte Inc425.33m-9.27m3.02bn815.00--2.57211.427.10-0.1445-0.14455.6115.180.35457.409.66521,878.50-0.7723-6.33-0.8157-6.6968.4567.10-2.18-20.994.79--0.00009--21.7631.45-103.51--39.67--
Dyne Therapeutics Inc0.00-294.51m3.03bn173.00--4.29-----3.56-3.560.006.930.00----0.00-60.47-52.81-65.37-57.45------------0.00-------40.36--40.32--
Edgewise Therapeutics Inc0.00-124.29m3.03bn108.00--6.18-----1.49-1.490.005.180.00----0.00-30.22---31.57--------------0.00-------48.08------
Agios Pharmaceuticals Inc32.87m727.43m3.17bn383.004.521.954.3296.3612.2811.370.577828.530.02350.159815.3185,825.0651.98-29.5455.50-31.8889.38--2,212.98-3,826.108.77--0.00--88.36-22.25-51.89---32.23--
MoonLake Immunotherapeutics0.00-80.77m3.31bn50.00--6.70-----1.29-1.290.007.740.00----0.00-16.25---18.06--------------0.00------27.95------
Denali Therapeutics Inc0.00-427.49m3.49bn390.00--2.64-----2.76-2.760.009.170.00----0.00-31.77-14.98-33.76-17.71-------104.50----0.0043--204.7420.6755.45--30.70--
Immunitybio Inc7.33m-587.79m3.51bn672.00------478.32-0.867-0.8670.0108-1.070.0184--1.5311,675.16-147.53-112.76-182.67-316.07-----8,018.00-37,700.742.64-2.194.22--159.1767.62-40.00--18.48--
Rhythm Pharmaceuticals Inc112.53m-261.57m3.63bn226.00--323.37--32.24-4.31-4.311.862.490.31361.186.65497,920.30-72.15-47.21-90.85-52.8488.61---230.11-681.383.34--0.417--227.56---1.97---42.10--
Alvotech SA393.92m-441.45m3.75bn999.00------9.52-1.90-1.901.56-1.290.35951.564.24394,313.30-40.28---47.87--59.03---112.07--1.92-0.05191.41--9.84---7.43------
Immunovant Inc0.00-323.01m3.90bn207.00--8.66-----2.21-2.210.003.060.00----0.00-79.97---92.17--------------0.00-------22.93------
Data as of Nov 22 2024. Currency figures normalised to Immunitybio Inc's reporting currency: US Dollar USD

Institutional shareholders

6.78%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 202416.55m2.38%
BlackRock Fund Advisorsas of 30 Sep 202410.26m1.47%
SSgA Funds Management, Inc.as of 30 Sep 20248.65m1.24%
Geode Capital Management LLCas of 30 Sep 20243.85m0.55%
Morgan Stanley & Co. LLCas of 30 Sep 20241.94m0.28%
MultiConcept Fund Management SAas of 30 Sep 20241.30m0.19%
Charles Schwab Investment Management, Inc.as of 30 Sep 20241.27m0.18%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 20241.22m0.18%
Millennium Management LLCas of 30 Sep 20241.12m0.16%
Bank of America, NA (Private Banking)as of 30 Sep 20241.10m0.16%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.